Glycogen synthase kinase 3β and leukemia
10.3760/cma.j.issn.1673-422X.2013.05.017
- VernacularTitle:糖原合成酶激酶3β与白血病
- Author:
Yan WANG
;
Youhua XU
- Publication Type:Journal Article
- Keywords:
Glycogen synthase kinase 3;
Leukemia;
Signal transduction;
Molecular targeted therapy
- From:
Journal of International Oncology
2013;(5):373-376
- CountryChina
- Language:Chinese
-
Abstract:
Glycogen synthase kinase 3β (GSK3 β) is a conserved cytoplasmic serine/threonine protein kinase.It can not only negatively regulate the classical Wnt and Akt signal pathways which are associated with leukemia,but also positively regulate the NF-κB,non-classical Wnt and lysosomal apoptosis signal pathways,thereby regulating the proliferation,differentiation and apoptosis of leukemia cells.At present,a variety of GSK.3 β inhibitors and activators have been reported in the researches of leukemia,which play important roles in reducing the adverse reactions of chemotherapy,reversing multidrug resistance and enhancing killing effect to leukemia cells.GSK3β is expected to become a target of leukemia molecular targeted therapy.
